Observational study of adults with Acute Myeloid Leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to observe adult patients diagnosed with Acute Myeloid Leukemia (AML) to understand the evolving landscape of diagnosis and treatment options over the past fifteen years. It will include patients who are newly diagnosed, untreated, or those with relapsed/refractory AML, focusing on the diversity of patient journeys influenced by genetic and prognostic factors. The study will document the standard treatment options available, including various chemotherapy regimens and the use of new drugs, while also considering the characteristics of each patient. Amendments may be made to the study as new treatment standards emerge.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient aged 18 years old or more
* Patient with newly diagnosed previously untreated de novo, secondary or therapy-related AML
* Patients with R/R de novo, secondary or therapy-related AML
* Patient with Health insurance

Exclusion Criteria:

* Acute promyelocytic leukemia
* AML which is not morphologically proven (patients with granulocytic sarcoma may be included)
* For newly diagnosed AML: previous treatment of leukemia apart from hydroxyurea. Previous anti leukemia treatments are allowed if they were administered before the diagnosis of AML to treat a MDS, MPN, MPN/MDS or CML
* Patient weighting less than 50 kgs
* Opposition of the patient to participate to this non-interventional study

More specific eligibility criteria might be requested to enter some study modules

Where it's running

• Chu Amiens
  Amiens, France Recruiting
• Centre Hospitalier Victor Dupouy
  Argenteuil, France Recruiting
• AP-HP-GHU - Hôpital AVICENNE
  Bobigny, France Recruiting
• CHU de la cote de Nacre
  Caen, France Recruiting
• Hôpital MILITAIRE PERCY
  Clamart, France Recruiting
• Centre hospitalier Sud Francilien
  Corbeil-Essonnes, France Recruiting

Study contacts

• Study coordinator: Karine CELLI LEBRAS, Mrs
• Email: karine.cellilebras@alfa-leukemia.org
• Phone: 33 1 57 27 67 17

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PBSS1113 with azacitidine for AML and higher-risk MDS

  This study tests PBSS1113 together with azacitidine to see if it is safe and may help people with AML or higher-risk MDS who are newly diagnosed and not fit for intense chemotherapy or who have relapsed/refractory disease.

  Recruiting Phase 1/2 Chaser Therapeutics, Inc. · Hangzhou, Zhejiang · NCT07761533

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Venetoclax TDM in newly diagnosed AML: exposure and prognosis

  This study checks if measuring venetoclax levels and adjusting treatment helps people with newly diagnosed AML who are getting VEN-AZA.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou · NCT07670130

• CAR-T cells targeting CD33 and CLL1 for relapsed or refractory AML

  A one-arm early-stage trial tests whether a patient’s own engineered CAR-T cells (ICG415) can be safely given after conditioning chemotherapy to see if they can help adults with relapsed or refractory AML.

  Recruiting at 2 sites Phase 1 iCell Gene Therapeutics · Nanchang, Jiangxi and 1 other locations · NCT07668557

• Ziftomenib for relapsed/refractory NPM1-mutated AML in Japanese adults

  This study will test whether ziftomenib can help adults with relapsed or refractory NPM1-mutated AML who have few other options.

  Recruiting at 15 sites Phase 2 Kyowa Kirin Co., Ltd. · Chiba and 19 other locations · NCT07623616

• VABu Conditioning for elderly AML patients undergoing stem cell transplant

  This trial tests a VABu conditioning regimen to see if it helps older AML patients before allogeneic stem cell transplantation.

  Recruiting Phase 2/3 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07583888

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.